美国最高法院以破产法限制为由，驳回了与普渡制药达成的 60 亿美元阿片类药物和解协议。 US Supreme Court rejects $6bn opioid settlement with Purdue Pharma, citing bankruptcy law restrictions.

美国最高法院驳回了与奥施康定生产商普渡制药达成的 60 亿美元阿片类药物和解协议，该协议本将提供数十亿美元用于抗击阿片类药物泛滥，并保护该公司所有者萨克勒家族免受进一步的民事诉讼。 The US Supreme Court has rejected a $6bn opioid settlement with OxyContin maker Purdue Pharma, which would have provided billions to combat the opioid epidemic and shielded the Sackler family, who own the company, from further civil lawsuits. 该决定以 5 比 4 的投票结果做出，可能对其他重大破产协议产生重大影响，其中包括美国童子军的 24 亿美元破产计划。 The decision, made in a 5-4 vote, has potentially significant implications for other major bankruptcy agreements, including the $2.4bn bankruptcy plan for the Boy Scouts of America. 法院裁定，破产法不允许向那些没有自己申请破产的人提供此类保护。 The court ruled that granting such protections to those who did not file for bankruptcy themselves was not permitted under bankruptcy law.